René M Botnar1,2,3,4, Julia Brangsch5, Carolin Reimann5, Christian H P Janssen1, Reza Razavi1,2,3,4, Bernd Hamm5, Marcus R Makowski6,5. 1. Division of Imaging Sciences, King's College London, London, United Kingdom. 2. BHF Centre of Excellence, King's College London, London, United Kingdom. 3. Wellcome Trust and EPSRC Medical Engineering Center, King's College London, London, United Kingdom. 4. NIHR Biomedical Research Centre, King's College London, London, United Kingdom. 5. Department of Radiology, Charite, Berlin, Germany. 6. Division of Imaging Sciences, King's College London, London, United Kingdom marcus.makowski@charite.de marcus.makowski@kcl.ac.uk.
Abstract
BACKGROUND: The incidence of abdominal aortic aneurysms (AAAs) will significantly increase during the next decade. Novel biomarkers, besides diameter, are needed for a better characterization of aneurysms and the estimation of the risk of rupture. Fibrin is a key protein in the formation of focal hematoma associated with the dissection of the aortic wall and the development of larger thrombi during the progression of AAAs. This study evaluated the potential of a fibrin-specific magnetic resonance (MR) probe for the in vivo characterization of the different stages of AAAs. METHODS AND RESULTS: AAAs spontaneously developed in ApoE-/- mice following the infusion of angiotensin-II (Ang-II, 1 μg/kg-1·per minute). An established fibrin-specific molecular MR probe (EP2104R, 10 μmol/kg-1) was administered after 1 to 4 weeks following Ang-II infusion (n=8 per group). All imaging experiments were performed on a clinical 3T Achieva MR system with a microscopy coil (Philips Healthcare, Netherlands). The development of AAA-associated fibrin-rich hematoma and thrombi was assessed. The high signal generated by the fibrin probe enabled high-resolution MR imaging for an accurate assessment and quantification of the relative fibrin composition of focal hematoma and thrombi. Contrast-to-noise-ratios (CNRs) and R1-relaxation rates following the administration of the fibrin probe were in good agreement with ex vivo immunohistomorphometry (R2=0.83 and 0.85) and gadolinium concentrations determined by inductively coupled plasma mass spectroscopy (R2=0.78 and 0.72). CONCLUSIONS: The fibrin-specific molecular MR probe allowed the delineation and quantification of changes in fibrin content in early and advanced AAAs. Fibrin MRI could provide a novel in vivo biomarker to improve the risk stratification of patients with aortic aneurysms.
BACKGROUND: The incidence of abdominal aortic aneurysms (AAAs) will significantly increase during the next decade. Novel biomarkers, besides diameter, are needed for a better characterization of aneurysms and the estimation of the risk of rupture. Fibrin is a key protein in the formation of focal hematoma associated with the dissection of the aortic wall and the development of larger thrombi during the progression of AAAs. This study evaluated the potential of a fibrin-specific magnetic resonance (MR) probe for the in vivo characterization of the different stages of AAAs. METHODS AND RESULTS: AAAs spontaneously developed in ApoE-/- mice following the infusion of angiotensin-II (Ang-II, 1 μg/kg-1·per minute). An established fibrin-specific molecular MR probe (EP2104R, 10 μmol/kg-1) was administered after 1 to 4 weeks following Ang-II infusion (n=8 per group). All imaging experiments were performed on a clinical 3T Achieva MR system with a microscopy coil (Philips Healthcare, Netherlands). The development of AAA-associated fibrin-rich hematoma and thrombi was assessed. The high signal generated by the fibrin probe enabled high-resolution MR imaging for an accurate assessment and quantification of the relative fibrin composition of focal hematoma and thrombi. Contrast-to-noise-ratios (CNRs) and R1-relaxation rates following the administration of the fibrin probe were in good agreement with ex vivo immunohistomorphometry (R2=0.83 and 0.85) and gadolinium concentrations determined by inductively coupled plasma mass spectroscopy (R2=0.78 and 0.72). CONCLUSIONS: The fibrin-specific molecular MR probe allowed the delineation and quantification of changes in fibrin content in early and advanced AAAs. Fibrin MRI could provide a novel in vivo biomarker to improve the risk stratification of patients with aortic aneurysms.
Authors: Femke A M V I Hellenthal; Willem A Buurman; Will K W H Wodzig; Geert Willem H Schurink Journal: Nat Rev Cardiol Date: 2009-05-26 Impact factor: 32.419
Authors: Marc Sirol; Valentin Fuster; Juan J Badimon; John T Fallon; Pedro R Moreno; Jean-François Toussaint; Zahi A Fayad Journal: Circulation Date: 2005-09-06 Impact factor: 29.690
Authors: S Flacke; S Fischer; M J Scott; R J Fuhrhop; J S Allen; M McLean; P Winter; G A Sicard; P J Gaffney; S A Wickline; G M Lanza Journal: Circulation Date: 2001-09-11 Impact factor: 29.690
Authors: Patrick M Winter; Shelton D Caruthers; Xin Yu; Sheng-Kwei Song; Junjie Chen; Brad Miller; Jeff W M Bulte; J David Robertson; Patrick J Gaffney; Samuel A Wickline; Gregory M Lanza Journal: Magn Reson Med Date: 2003-08 Impact factor: 4.668
Authors: René M Botnar; Andrea J Wiethoff; Ullrich Ebersberger; Sara Lacerda; Ulrike Blume; Alice Warley; Christian H P Jansen; David C Onthank; Richard R Cesati; Reza Razavi; Michael S Marber; Bernd Hamm; Tobias Schaeffter; Simon P Robinson; Marcus R Makowski Journal: Circ Cardiovasc Imaging Date: 2014-05-28 Impact factor: 7.792
Authors: Ketan B Ghaghada; Pingping Ren; Laxman Devkota; Zbigniew Starosolski; Chen Zhang; Deborah Vela; Igor V Stupin; Eric A Tanifum; Ananth V Annapragada; Ying H Shen; Scott A LeMaire Journal: Arterioscler Thromb Vasc Biol Date: 2021-02-04 Impact factor: 8.311
Authors: Federico Collettini; Carolin Reimann; Julia Brangsch; Julius Chapiro; Lynn Jeanette Savic; David C Onthank; Simon P Robinson; Uwe Karst; Rebecca Buchholz; Sarah Keller; Bernd Hamm; S Nahum Goldberg; Marcus R Makowski Journal: Sci Rep Date: 2021-03-25 Impact factor: 4.379
Authors: Vinamr Rastogi; Sanne J M Stefens; Judith Houwaart; Hence J M Verhagen; Jorg L de Bruin; Ingrid van der Pluijm; Jeroen Essers Journal: Front Med (Lausanne) Date: 2022-04-15